Drugs / FS-8002
last change Feb 2025 re-read 2 minutes ago

FS-8002

Developed for
cancer
Investigated by
Shanghai Pushi Medical Science Co. Ltd

Trials 1 · a red edge is where a trial was stopped

202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06832982 Feb 2025 → Feb 2028 expected cancer Shanghai Pushi Medical Science Co. Ltd Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as FS-8002 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06832982